As filed with the Securities and Exchange Commission on August 11, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
____________________________________________
X4 Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
___________________________________________
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
| Delaware | | 27-3181608 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
| |
61 North Beacon Street, 4th Floor Boston, Massachusetts | | 02134 |
| (Address of Principal Executive Offices) | | (Zip Code) |
X4 Pharmaceuticals, Inc. Amended and Restated 2017 Employee Stock Purchase Plan
X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan
(Full title of the plan)
Paula Ragan, Ph.D.
President and Chief Executive Officer
X4 Pharmaceuticals, Inc.
61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
(857) 529-8300
(Name, address and telephone number, including area code, of agent for service)
___________________________
Copy to:
Daniel I. Goldberg
Courtney T. Thorne
Cooley LLP
55 Hudson Yards
New York, NY 10001-2157
(212) 479-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement on Form S-8 is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 of the Registrant relating to the same employee benefit plans is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8 (File No. 333-221622) filed with the Securities and Exchange Commission (“SEC”) on November 16, 2017 relating to the Registrant’s 2010 Special Stock Incentive Plan, 2011 Stock Incentive Plan, the 2017 Equity Incentive Plan (as amended and restated from time to time, the “2017 Plan”) and the 2017 Employee Stock Purchase Plan (as amended and restated from time to time, the “2017 ESPP”); (ii) the Registration Statement on Form S-8 (File No. 333-223539) filed with the SEC on March 9, 2018 relating to the Registrant’s 2017 Plan; (iii) the Registration Statement on Form S-8 (File No. 333-230181) filed with the SEC on March 11, 2019 relating to the 2017 Plan and the 2017 ESPP; (iv) the Registration Statement on Form S-8 (File No. 333-233162) filed with the SEC on August 9, 2019 relating to the 2019 Inducement Equity Incentive Plan (as amended and restated from time to time, the “Inducement Plan”); (v) the Registration Statement on Form S-8 (File No. 333-237164) filed with the SEC on March 13, 2020 relating to the 2017 Plan, the 2017 ESPP and the Inducement Plan; (vi) the Registration Statement on Form S-8 (File No 333-239082) filed with the SEC on June 10, 2020 relating to the 2017 Plan; (vii) the Registration Statement on Form S-8 (File No 333-254618) filed with the SEC on March 23, 2021 relating to the 2017 Plan, the 2017 ESPP and the Inducement Plan and (viii) the Registration Statement on Form S-8 (File No 333-263430) filed with the SEC on March 10, 2022 relating to the 2017 Plan, the 2017 ESPP and the Inducement Plan; and (ix) the Registration Statement on Form S-8 (File No 333-269335) filed with the SEC on January 20, 2023 relating to the 2017 Plan, the 2017 ESPP and the Inducement Plan, in each case except for Item 8, Exhibits, with respect to which the Exhibit Index below is incorporated herein by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Exhibit Number | Exhibit Description | Filed Herewith | Incorporated Reference herein from Form or Schedule | Filing Date | SEC File/Reg. Number |
| 4.1 | | | 8-K
(Exhibit 3.1) | 9/1/2022 | 001-38295 |
| 4.2 | | | 8-K
(Exhibit 3.2) | 11/20/2017 | 001-38295 |
| 4.3 | | | 8-K
(Exhibit 4.1) | 03/13/2019 | 001-38295 |
| 5.1 | | X | | | |
| 23.1 | | X | | | |
| 23.2 | | X | | | |
| 24.1 | | X | | | |
| 99.1 | | X | | | |
| 99.2 | | X | | | |
| 99.3 | | | 8-K
(Exhibit 10.2) | 6/19/2019 | 001-38295 |
| 99.4 |
| | 8-K
(Exhibit 10.3) | 6/19/2019 | 001-38295 |
| 99.5 | | | 8-K
(Exhibit 10.4) | 06/19/2019 | 001-38295 |
| 107 | | X | | | |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on August 11, 2023.
X4 PHARMACEUTICALS, INC.
By: /s/ Paula Ragan, Ph.D
Paula Ragan, Ph.D.
President and Chief Executive Officer
SIGNATURES AND POWER OF ATTORNEY
We, the undersigned officers and directors of X4 Pharmaceuticals, Inc., hereby severally constitute and appoint Paula Ragan, Ph.D. and Adam S. Mostafa, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of X4 Pharmaceuticals, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Signature | | Title | | Date |
| | |
| /s/ Paula Ragan | | President, Chief Executive Officer and Director (principal executive officer) | | August 11, 2023 |
| Paula Ragan, Ph.D. | | |
| | |
| /s/ Adam S. Mostafa | | Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer) | | August 11, 2023 |
| Adam S. Mostafa | | |
| | |
| /s/ Michael S. Wyzga | | Chairman of the Board of Directors | | August 11, 2023 |
| Michael S. Wyzga | | |
| | |
| /s/ William E. Aliski | | Director | | August 11, 2023 |
| William E. Aliski | | |
| | |
| /s/ Gary J. Bridger | | Director | | August 11, 2023 |
| Gary J. Bridger, Ph.D. | | |
| | |
| /s/ Francoise De Craecker | | Director | | August 11, 2023 |
| Francoise De Craecker | | |
| | | | | | | | | | |
| /s/ Alison F. Lawton | | Director | | August 11, 2023 |
| Alison F. Lawton | | |
| | |
| /s/ David McGirr | | Director | | August 11, 2023 |
| David McGirr, M.B.A. | | |
|
| /s/ Murray W. Stewart, M.D. | | Interim Chief Medical Officer and Director | | August 11, 2023 |
| Murray W. Stewart, M.D. | | |
